Literature DB >> 31780287

Differences between KC and KPC pancreatic ductal adenocarcinoma mice models, in terms of their modeling biology and their clinical relevance.

Abakundanda Nsenga Ariston Gabriel1, Qinlian Jiao2, Umwali Yvette3, Xuemei Yang1, Samed A Al-Ameri1, Lutao Du1, Yun-Shan Wang4, Chuanxin Wang5.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is among the dangerous human cancers, is the 10th highly prevalent cancer, and the fourth sole cause of cancer-related mortality in the United States of America. Notwithstanding the significant commitment, the forecast for people with this burden continues to have a five-year survival rate of just 4-6%. The most critical altered genes within PDAC consist of K-ras the proto-oncogene which is usually mutationally activated above 90% cases and tumor suppressors likeTrp53 are altered at 55%. To face the burden of pancreatic ductal adenocarcinoma, a variety of genetically engineered pancreatic cancer mice models have been created over the last past years. These models have distinctive features and are not all appropriate for preclinical studies. In this review, we focus on differences between two mice models K-rasLSL.G12D/+;Pdx-1-Cre(KC) and K-rasLSL.G12D/+; Trp53R172H/+; Pdx-1-Cre(KPC) in terms of their modeling biology and their clinical relevance.
Copyright © 2019 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical relevance; Genetic engineered mouse model; KC and KPC; Modeling biology; Pancreatic ductal adenocarcinoma

Mesh:

Year:  2019        PMID: 31780287     DOI: 10.1016/j.pan.2019.11.006

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  8 in total

Review 1.  Pancreatic cancer: branched-chain amino acids as putative key metabolic regulators?

Authors:  Lenka Rossmeislová; Jan Gojda; Katarína Smolková
Journal:  Cancer Metastasis Rev       Date:  2021-12-28       Impact factor: 9.264

Review 2.  A Comprehensive Review of the Current and Future Role of the Microbiome in Pancreatic Ductal Adenocarcinoma.

Authors:  Nabeel Merali; Tarak Chouari; Kayani Kayani; Charles J Rayner; José I Jiménez; Jonathan Krell; Elisa Giovannetti; Izhar Bagwan; Kate Relph; Timothy A Rockall; Tony Dhillon; Hardev Pandha; Nicola E Annels; Adam E Frampton
Journal:  Cancers (Basel)       Date:  2022-02-17       Impact factor: 6.639

3.  Genetic Mouse Models to Study Pancreatic Cancer-Induced Pain and Reduction in Well-Being.

Authors:  Michael Hirth; Yong Xie; Christiane Höper; Amandine Prats; Thilo Hackert; Matthias P Ebert; Rohini Kuner
Journal:  Cells       Date:  2022-08-24       Impact factor: 7.666

Review 4.  Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects.

Authors:  Silviu Stanciu; Florentina Ionita-Radu; Constantin Stefani; Daniela Miricescu; Iulia-Ioana Stanescu-Spinu; Maria Greabu; Alexandra Ripszky Totan; Mariana Jinga
Journal:  Int J Mol Sci       Date:  2022-09-04       Impact factor: 6.208

5.  Inhibition of de novo pyrimidine synthesis augments Gemcitabine induced growth inhibition in an immunocompetent model of pancreatic cancer.

Authors:  Thuy Phan; Vu H Nguyen; Ralf Buettner; Corey Morales; Lifeng Yang; Paul Wong; Weiman Tsai; Marcela d'Alincourt Salazar; Ziv Gil; Don J Diamond; Joshua D Rabinowitz; Steven Rosen; Laleh G Melstrom
Journal:  Int J Biol Sci       Date:  2021-06-01       Impact factor: 6.580

Review 6.  Fungi, host immune response, and tumorigenesis.

Authors:  Miar Elaskandrany; Rohin Patel; Mintoo Patel; George Miller; Deepak Saxena; Anjana Saxena
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2021-07-07       Impact factor: 4.871

7.  Identification of the Neurokinin-1 Receptor as Targetable Stratification Factor for Drug Repurposing in Pancreatic Cancer.

Authors:  Iris Beirith; Bernhard W Renz; Shristee Mudusetti; Natalja Sergejewna Ring; Julian Kolorz; Dominik Koch; Alexandr V Bazhin; Michael Berger; Jing Wang; Martin K Angele; Jan G D'Haese; Markus O Guba; Hanno Niess; Joachim Andrassy; Jens Werner; Matthias Ilmer
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

8.  Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.

Authors:  Juan Zhang; Hong-Xi Xu; William Chi Shing Cho; Wah Cheuk; Yang Li; Qiong-Hui Huang; Wen Yang; Yan-Fang Xian; Zhi-Xiu Lin
Journal:  J Exp Clin Cancer Res       Date:  2022-03-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.